First Time Loading...

Uniqure NV
NASDAQ:QURE

Watchlist Manager
Uniqure NV Logo
Uniqure NV
NASDAQ:QURE
Watchlist
Price: 4.56 USD -4%
Updated: Apr 25, 2024

Intrinsic Value

QURE's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. [ Read More ]

The intrinsic value of one QURE stock under the Base Case scenario is 14.18 USD. Compared to the current market price of 4.56 USD, Uniqure NV is Undervalued by 68%.

Key Points:
QURE Intrinsic Value
Base Case
14.18 USD
Undervaluation 68%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Uniqure NV

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling QURE stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Uniqure NV

Provide an overview of the primary business activities
of Uniqure NV.

What unique competitive advantages
does Uniqure NV hold over its rivals?

What risks and challenges
does Uniqure NV face in the near future?

Has there been any significant insider trading activity
in Uniqure NV recently?

Summarize the latest earnings call
of Uniqure NV.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Uniqure NV.

Provide P/S
for Uniqure NV.

Provide P/E
for Uniqure NV.

Provide P/OCF
for Uniqure NV.

Provide P/FCFE
for Uniqure NV.

Provide P/B
for Uniqure NV.

Provide EV/S
for Uniqure NV.

Provide EV/GP
for Uniqure NV.

Provide EV/EBITDA
for Uniqure NV.

Provide EV/EBIT
for Uniqure NV.

Provide EV/OCF
for Uniqure NV.

Provide EV/FCFF
for Uniqure NV.

Provide EV/IC
for Uniqure NV.

Show me price targets
for Uniqure NV made by professional analysts.

What are the Revenue projections
for Uniqure NV?

How accurate were the past Revenue estimates
for Uniqure NV?

What are the Net Income projections
for Uniqure NV?

How accurate were the past Net Income estimates
for Uniqure NV?

What are the EPS projections
for Uniqure NV?

How accurate were the past EPS estimates
for Uniqure NV?

What are the EBIT projections
for Uniqure NV?

How accurate were the past EBIT estimates
for Uniqure NV?

Compare the revenue forecasts
for Uniqure NV with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Uniqure NV and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Uniqure NV against its competitors.

Analyze the profit margins
(gross, operating, and net) of Uniqure NV compared to its peers.

Compare the P/E ratios
of Uniqure NV against its peers.

Discuss the investment returns and shareholder value creation
comparing Uniqure NV with its peers.

Analyze the financial leverage
of Uniqure NV compared to its main competitors.

Show all profitability ratios
for Uniqure NV.

Provide ROE
for Uniqure NV.

Provide ROA
for Uniqure NV.

Provide ROIC
for Uniqure NV.

Provide ROCE
for Uniqure NV.

Provide Gross Margin
for Uniqure NV.

Provide Operating Margin
for Uniqure NV.

Provide Net Margin
for Uniqure NV.

Provide FCF Margin
for Uniqure NV.

Show all solvency ratios
for Uniqure NV.

Provide D/E Ratio
for Uniqure NV.

Provide D/A Ratio
for Uniqure NV.

Provide Interest Coverage Ratio
for Uniqure NV.

Provide Altman Z-Score Ratio
for Uniqure NV.

Provide Quick Ratio
for Uniqure NV.

Provide Current Ratio
for Uniqure NV.

Provide Cash Ratio
for Uniqure NV.

What is the historical Revenue growth
over the last 5 years for Uniqure NV?

What is the historical Net Income growth
over the last 5 years for Uniqure NV?

What is the current Free Cash Flow
of Uniqure NV?

Discuss the annual earnings per share (EPS)
trend over the past five years for Uniqure NV.

Financials

Balance Sheet Decomposition
Uniqure NV

Current Assets 651.9m
Cash & Short-Term Investments 617.9m
Receivables 4.2m
Other Current Assets 29.8m
Non-Current Assets 179.8m
PP&E 75.3m
Intangibles 86.9m
Other Non-Current Assets 17.6m
Current Liabilities 73.7m
Accounts Payable 6.6m
Accrued Liabilities 38.9m
Other Current Liabilities 28.2m
Non-Current Liabilities 550.3m
Long-Term Debt 496m
Other Non-Current Liabilities 54.4m
Efficiency

Earnings Waterfall
Uniqure NV

Revenue
15.8m USD
Cost of Revenue
-13.6m USD
Gross Profit
2.2m USD
Operating Expenses
-285.1m USD
Operating Income
-282.9m USD
Other Expenses
-25.6m USD
Net Income
-308.5m USD

Free Cash Flow Analysis
Uniqure NV

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
Fundamental Scores

QURE Profitability Score
Profitability Due Diligence

Uniqure NV's profitability score is 32/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Exceptional Revenue Growth Forecast
ROIC is Increasing
Positive 3-Year Average ROIC
32/100
Profitability
Score

Uniqure NV's profitability score is 32/100. The higher the profitability score, the more profitable the company is.

QURE Solvency Score
Solvency Due Diligence

Uniqure NV's solvency score is 35/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Negative Net Debt
Long-Term Solvency
High D/E
35/100
Solvency
Score

Uniqure NV's solvency score is 35/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

QURE Price Targets Summary
Uniqure NV

Wall Street analysts forecast QURE stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for QURE is 21.26 USD with a low forecast of 7.07 USD and a high forecast of 31.5 USD.

Lowest
Price Target
7.07 USD
55% Upside
Average
Price Target
21.26 USD
366% Upside
Highest
Price Target
31.5 USD
591% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

QURE Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

QURE Price
Uniqure NV

1M 1M
-15%
6M 6M
-22%
1Y 1Y
-77%
3Y 3Y
-87%
5Y 5Y
-92%
10Y 10Y
-59%
Annual Price Range
4.56
52w Low
4.56
52w High
22.2
Price Metrics
Average Annual Return -15.79%
Standard Deviation of Annual Returns 34.64%
Max Drawdown -94%
Shares Statistics
Market Capitalization 218.1m USD
Shares Outstanding 47 840 000
Percentage of Shares Shorted 6.05%

QURE Return Decomposition
Main factors of price return

What is price return decomposition?

QURE News

Other Videos

Company Profile

Uniqure NV Logo
Uniqure NV

Country

Netherlands

Industry

Biotechnology

Market Cap

218.1m USD

Dividend Yield

0%

Description

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. The company is headquartered in Amsterdam, Noord-Holland and currently employs 463 full-time employees. The company went IPO on 2014-02-05. The company seeks to develop one-time administered treatments with potentially curative results for patients suffering from genetic and other devastating diseases. The company develops, both internally and through partnerships, a pipeline of gene therapies. The company produces adeno-associated virus based, or AAV-based, gene therapies in its own facilities with a proprietary, commercial-scale, current good manufacturing practices, compliant, manufacturing process. AMT-061, the Company’s lead product candidate for patients with hemophilia B, is going through a dosing phase of a pivotal study. AMT-130, the product candidate for patients with Huntington’s disease is in Phase I/II clinical study.

Contact

NOORD-HOLLAND
Amsterdam
Paasheuvelweg 25a
+31202406000.0
http://www.uniqure.com/

IPO

2014-02-05

Employees

463

Officers

CEO & Executive Director
Mr. Matthew Craig Kapusta
CFO, Principal Financial Officer & GM of Amsterdam Site
Mr. Christian Klemt
Chief Operating Officer
Mr. Pierre Caloz
Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany
Prof. Hugo Katus
Chief Business & Scientific Officer
Mr. Richard Porter Ph.D.
Chief Legal & Compliance Officer
Dr. Jeannette Potts J.D., Ph.D.
Show More
Business Development Director
Dr. Tamara Tugal Ph.D., MBA
Interim Chief People and Culture Officer
Ms. Carla Poulson
Chief Corporate Affairs Officer
Ms. Maria E. Cantor
Chief Quality Officer
Dr. Amin Abujoub Ph.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one QURE stock?

The intrinsic value of one QURE stock under the Base Case scenario is 14.18 USD.

Is QURE stock undervalued or overvalued?

Compared to the current market price of 4.56 USD, Uniqure NV is Undervalued by 68%.